149 related articles for article (PubMed ID: 11829281)
21. Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations.
Kirkwood JM; Moschos S; Wang W
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2331s-2336s. PubMed ID: 16609054
[TBL] [Abstract][Full Text] [Related]
22. Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy.
O'Day SJ; Boasberg PD; Piro L; Kristedja TS; Wang HJ; Martin M; Deck R; Ames P; Shinn K; Kim H; Fournier P; Gammon G
Clin Cancer Res; 2002 Sep; 8(9):2775-81. PubMed ID: 12231516
[TBL] [Abstract][Full Text] [Related]
23. GM-CSF and IL-2 combination as adjuvant therapy in cutaneous melanoma: early results of a phase II clinical trial.
Elias EG; Zapas JL; Beam SL; Brown SD
Oncology (Williston Park); 2005 Apr; 19(4 Suppl 2):15-8. PubMed ID: 15934495
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapy as an adjuvant therapy in the management of advanced, surgically resected, melanoma.
Kalani AD; Jack A; Montenegro G; Degliuomini J; Wallack MK
G Ital Dermatol Venereol; 2008 Feb; 143(1):59-70. PubMed ID: 18833052
[TBL] [Abstract][Full Text] [Related]
25. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate.
Hofbauer GF; Baur T; Bonnet MC; Tartour E; Burg G; Berinstein NL; Dummer R
Melanoma Res; 2008 Apr; 18(2):104-11. PubMed ID: 18337646
[TBL] [Abstract][Full Text] [Related]
26. [Melanoma].
Saida T
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1386-91. PubMed ID: 17033225
[TBL] [Abstract][Full Text] [Related]
27. A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation.
Elkordy M; Crump M; Vredenburgh JJ; Petros WP; Hussein A; Rubin P; Ross M; Gilbert C; Modlin C; Meisenberg B; Coniglio D; Rabinowitz J; Laughlin M; Kurtzberg J; Peters WP
Bone Marrow Transplant; 1997 Feb; 19(4):315-22. PubMed ID: 9051240
[TBL] [Abstract][Full Text] [Related]
28. Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor.
Daud AI; Mirza N; Lenox B; Andrews S; Urbas P; Gao GX; Lee JH; Sondak VK; Riker AI; Deconti RC; Gabrilovich D
J Clin Oncol; 2008 Jul; 26(19):3235-41. PubMed ID: 18591558
[TBL] [Abstract][Full Text] [Related]
29. Determination of potential adjuvant systemic therapy benefits for patients with resected cutaneous melanomas.
Thomé SD; Loprinzi CL; Heldebrant MP
Mayo Clin Proc; 2002 Sep; 77(9):913-7. PubMed ID: 12233924
[TBL] [Abstract][Full Text] [Related]
30. Melanoma adjuvant therapy.
Tarhini AA; Thalanayar PM
Hematol Oncol Clin North Am; 2014 Jun; 28(3):471-89. PubMed ID: 24880942
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors in patients with localized primary cutaneous melanoma.
Mervic L
Acta Dermatovenerol Alp Pannonica Adriat; 2012; 21(2):27-31. PubMed ID: 23000937
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant GM-CSF improves survival in high-risk stage iiic melanoma: a single-center Study.
Grotz TE; Kottschade L; Pavey ES; Markovic SN; Jakub JW
Am J Clin Oncol; 2014 Oct; 37(5):467-72. PubMed ID: 23428946
[TBL] [Abstract][Full Text] [Related]
33. Granulocyte-macrophage colony-stimulating factor: another cytokine with adjuvant therapeutic benefit in melanoma?
Lawson D; Kirkwood JM
J Clin Oncol; 2000 Apr; 18(8):1603-5. PubMed ID: 10764419
[No Abstract] [Full Text] [Related]
34. [Adjuvant therapy of malignant melanoma].
Hauschild A; Volkenandt M
Ther Umsch; 1999 Jun; 56(6):324-9. PubMed ID: 10420815
[TBL] [Abstract][Full Text] [Related]
35. Variations in management of stage I to stage III cutaneous melanoma: a population-based study of clinical practices in France.
Grange F; Vitry F; Granel-Brocard F; Lipsker D; Aubin F; Hédelin G; Dalac S; Truchetet F; Michel C; Batard ML; Baury B; Halna JM; Schmutz JL; Delvincourt C; Reuter G; Dalle S; Bernard P; Danzon A
Arch Dermatol; 2008 May; 144(5):629-36. PubMed ID: 18490589
[TBL] [Abstract][Full Text] [Related]
36. Prognostic factors in 1,521 melanoma patients with distant metastases.
Barth A; Wanek LA; Morton DL
J Am Coll Surg; 1995 Sep; 181(3):193-201. PubMed ID: 7670677
[TBL] [Abstract][Full Text] [Related]
37. [Adjuvant therapy of primary malignant melanoma with natural human interferon-beta. Significant survival advantage in 96 treated patients in comparison with 288 untreated symptomatic controls].
Beiteke U; Ruppert P; Garbe C; Oxenfarth R; Kastl I; Türker T; Tronnier H; Frosch PJ
Hautarzt; 1993 Jun; 44(6):365-71. PubMed ID: 8335459
[TBL] [Abstract][Full Text] [Related]
38. Interferon adjuvant therapy of melanoma.
Nathanson L
Cancer; 1996 Sep; 78(5):944-7. PubMed ID: 8780530
[No Abstract] [Full Text] [Related]
39. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma.
McMasters KM; Edwards MJ; Ross MI; Reintgen DS; Martin RC; Urist MM; Noyes RD; Sussman JJ; Stromberg AJ; Scoggins CR
Ann Surg; 2010 Sep; 252(3):460-5; discussion 465-6. PubMed ID: 20739846
[TBL] [Abstract][Full Text] [Related]
40. What's new in the treatment of cutaneous melanoma?
Olhoffer IH; Bolognia JL
Semin Cutan Med Surg; 1998 Jun; 17(2):96-107. PubMed ID: 9669603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
